BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11317960)

  • 1. Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.
    Cervantes F
    Pathol Biol (Paris); 2001 Mar; 49(2):148-52. PubMed ID: 11317960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
    Tefferi A
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):18-21. PubMed ID: 12682877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging.
    Cervantes F; Barosi G
    Semin Oncol; 2005 Aug; 32(4):395-402. PubMed ID: 16202685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment.
    Dingli D; Mesa RA; Tefferi A
    Intern Med; 2004 Jul; 43(7):540-7. PubMed ID: 15335177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.
    Mesa RA
    Curr Hematol Rep; 2003 May; 2(3):264-70. PubMed ID: 12901349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups.
    Cervantes F; Barosi G; Demory JL; Reilly J; Guarnone R; Dupriez B; Pereira A; Montserrat E
    Br J Haematol; 1998 Aug; 102(3):684-90. PubMed ID: 9722294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.
    Arora B; Ho CL; Hoyer JD; Mesa RA; Tefferi A
    Haematologica; 2004 Dec; 89(12):1454-8. PubMed ID: 15590395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.
    Dupriez B; Morel P; Demory JL; Lai JL; Simon M; Plantier I; Bauters F
    Blood; 1996 Aug; 88(3):1013-8. PubMed ID: 8704209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapy of myelofibrosis: targeting pathogenesis.
    Mesa RA
    Int J Hematol; 2002 Aug; 76 Suppl 2():296-304. PubMed ID: 12430941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modern management of myelofibrosis.
    Cervantes F
    Br J Haematol; 2005 Mar; 128(5):583-92. PubMed ID: 15725078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients.
    Visani G; Finelli C; Castelli U; Petti MC; Ricci P; Vianelli N; Gianni L; Zuffa E; Aloe Spiriti MA; Latagliata R
    Br J Haematol; 1990 May; 75(1):4-9. PubMed ID: 2375922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis.
    Tefferi A; Mudireddy M; Gangat N; Hanson CA; Ketterling RP; Pardanani A; Nagorney DM
    Am J Hematol; 2017 Nov; 92(11):1187-1192. PubMed ID: 28782256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches in the treatment of myelofibrosis.
    Hennessy BT; Thomas DA; Giles FJ; Kantarjian H; Verstovsek S
    Cancer; 2005 Jan; 103(1):32-43. PubMed ID: 15565565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival.
    Cervantes F; Barosi G; Hernández-Boluda JC; Marchetti M; Montserrat E
    Eur J Haematol; 2001 May; 66(5):324-7. PubMed ID: 11422412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.
    Arora B; Mesa R; Tefferi A
    Leuk Lymphoma; 2004 Dec; 45(12):2373-86. PubMed ID: 15621750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.
    Mesa RA; Barosi G; Cervantes F; Reilly JT; Tefferi A
    Best Pract Res Clin Haematol; 2006; 19(3):495-517. PubMed ID: 16781486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.
    Tefferi A; Mesa RA; Nagorney DM; Schroeder G; Silverstein MN
    Blood; 2000 Apr; 95(7):2226-33. PubMed ID: 10733489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.